Botanical species · safety record

Agathosma crenulata

The EFSA Compendium of Botanicals holds 20 constituent measurements for Agathosma crenulata. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Agathosma crenulata (L.) Pillans

20Constituent measurements

0Safety records

3Cited sources

11Licensed products (Canada)

Also recorded as

Barosma crenulata (L.) Hook.

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 11 licensed products naming Agathosma crenulata as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

Source material stated

Leaf

What the records describe

Constituents measured

Plant parts

Preparations

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
(+)-pulegone	Aerial part of plants	Essential oil	≤ 66 Percent	GC-MS	Resolve DOI
(+)-pulegone	Aerial part of plants	Essential oil	≥ 50 Percent	GC-MS	Resolve DOI
(+)-pulegone	Unspecified	Essential oil	53.75 Percent	GC-MS	Resolve DOI
1,8-cineole	Unspecified	Essential oil	1.19 Percent	GC-MS	Resolve DOI
Cis-isopulegone	Unspecified	Essential oil	2.78 Percent	GC-MS	Resolve DOI
Cis-isopulegone	Aerial part of plants	Essential oil	≤ 5 Percent	GC-MS	Resolve DOI
Cis-isopulegone	Aerial part of plants	Essential oil	≥ 1.7 Percent	GC-MS	Resolve DOI
D,l-isomenthone	Unspecified	Essential oil	3.58 Percent	GC-MS	Resolve DOI
D,l-isomenthone	Aerial part of plants	Essential oil	≥ 6 Percent	GC-MS	Resolve DOI
D,l-isomenthone	Aerial part of plants	Essential oil	≤ 15 Percent	GC-MS	Resolve DOI
Menthone	Unspecified	Essential oil	2.91 Percent	GC-MS	Resolve DOI
Menthone	Aerial part of plants	Essential oil	≤ 4 Percent	GC-MS	Resolve DOI
Menthone	Aerial part of plants	Essential oil	≥ 1 Percent	GC-MS	Resolve DOI
Monoterpene ketones	Unspecified	Essential oil	6.83 Percent	GC-MS	Resolve DOI
Monoterpene ketones	Unspecified	Essential oil	4.67 Percent	GC-MS	Resolve DOI
Monoterpene ketones	Leaves	Essential oil	—	GC-MS	Resolve DOI
Myrcene	Unspecified	Essential oil	1.01 Percent	GC-MS	Resolve DOI
Trans-isopulegone	Aerial part of plants	Essential oil	≤ 3.9 Percent	GC-MS	Resolve DOI
Trans-isopulegone	Aerial part of plants	Essential oil	≥ 2.1 Percent	GC-MS	Resolve DOI
Trans-isopulegone	Unspecified	Essential oil	2.77 Percent	GC-MS	Resolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Sandasi, M., Kamatou, G. P. P., Baranska, M., Viljoen, A. M. Application of vibrational spectroscopy in the quality assessment of Buchu oil obtained from two commercially important Agathosma species (Rutaceae) . South african journal of botany, 2010, vol. 76, no. 4, p. 692-700. DOI
Posthumus, M.A., van Beek, T.A., Collins, N.F., Graven, E.H. Chemical composition of the essential oils of agathosma betulina, A. Crenulata and an A. Betulina x crenulata Hybrid (buchu). Journal of essential oil research, 1996, vol. 8, no. 3, p. 223-228. DOI
Koepke, Thomas., Schmarr, Hans-Georg., Mosandl, Armin. Stereoisomeric Flavour Compounds. Part LVII: The Stereoisomers of 3-Oxo-p-menthane-8-thiol acetate, Simultaneously Stereoanalysed with their Corresponding Thiols . Flavour and fragrance journal, 1992, vol. 7, no. 4, p. 205-211. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature